<DOC>
	<DOCNO>NCT02168569</DOCNO>
	<brief_summary>This classical vivo clinical trial , follow World Health organization 's recommendation , run multisite study within Mozambique try assess efficacy safety 5 site two oral ACTS artemether-lumefantrine ( AL ) Amodiaquine-Artesunate ( AQ-AS ) , first second line treatment malaria mozambique , respectively , treatment uncomplicated malaria child age &lt; 5 year .</brief_summary>
	<brief_title>In Vivo Efficacy Artemether-lumefantrine Amodiaquine-artesunate Mozambican Children</brief_title>
	<detailed_description>This study follow WHO recommendation vivo antimalarial efficacy trial . The study population comprise child age 6 59 month microscopically confirm acute uncomplicated malaria . Other inclusion criterion include body weight ≥5kg , presence fever ( ≥37.5°C axillary ) history fever precede 24 hour , P. falciparum malaria mono infection asexual blood density ≥2,000/µL &lt; 200,000/µL , absence severe sign complicate malaria define WHO . Key exclusion criterion include mixed malarial infection , haemoglobin &lt; 5g/dL , severe malnutrition , intake anti-malarials within precede seven day , ongoing prophylaxis HIV positive patient cotrimoxazole intake drug anti-malarial activity , serious underlie disease . Patients satisfy inclusion criterion enrol parent/guardian sign detailed write informed consent . Eligible patient consecutively assign cohort treat AL ( cohort 1 ) AQ-AS ( cohort 2 ) . AL ( Coartem™ ) administer twice daily three day ( six dos total ) dosage determine accord body weight : one tablet ( 20mg artemether 120mg lumefantrine ) child 5 &lt; 15kg , two tablet per dose 15 &lt; 25kg , three tablet per dose 25 &lt; 35kg . AQ-AS ( Coarsucam™ ) administer daily accord body weight : one 25mg artesunate 67.5mg amodiaquine tablet child &lt; 9kg , one 50mg artesunate 135mg amodiaquine tablet child 9-17.9kg ; one 100mg artesunate 270mg amodiaquine tablet child &gt; 18-35kg . All treatment directly observe minimum 30 minute . Vomiting occur within first 30 minute implied repetition full dose treatment . For patient live far away health facility , direct observation evening dose AL challenging , admission offer first three day study . Antipyretics , paracetamol , use control fever &gt; =38ºC . In event severe malaria danger sign , patient hospitalize receive intravenous quinine , accord national malaria treatment policy . Rescue therapy accord national malaria treatment guideline also administer case early late treatment failure Follow-up visit take place day 1 , 2 , 3 , 7 , 14 , 28 enrolment time point whenever child sick . Patients prematurely discontinue either study drug study exclude study . Vital sign body temperature assess follow-up visit . Adverse event record assess severity association study medication . Thick thin Giemsa-stained blood slide prepare dose administer every follow-up visit day 2 , 3 , 7 , 14 , 21 28 . Slides examine two independent microscopist consider negative parasite see examination 200 oil-immersion field thick blood film . Species determination ( thus conformation monoinfection ) make base assessment thin film . Blood sample PCR analysis collect every patient baseline day 7 , 14 28 , day treatment failure unscheduled visit . PCR perform centrally case recurrent parasitaemia day 7 onwards distinguish recrudescence reinfection accord standardize WHO method</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Ages 6 59 month Weight Greater equal 5 kg Absence severe malnutrition ; Monoinfection Plasmodium falciparum blood , confirm microscopy ; Parasite density 2,000 200,000 asexual parasite per microliter blood ; Axillary temperature ≥ 37.5 C° history fever last 24 hour ; Lack danger sign , sign severe / complicate malaria accord WHO definition Ability swallow drug Haemoglobin great 5.0 g / dl Residents within study area possibility adequate followup day monitor period 28 day ; Absence history hypersensitivity study medication ; Informed consent parent , guardian caregiver ( legal guardian ) explain purpose study . Presence danger sign severe complicate Plasmodium falciparum malaria accord WHO definition Presence fever due disease malaria ( eg measles , acute respiratory infection , severe diarrhea dehydration ) know disease , chronic serious illness ( cardiac , renal , hepatic know infection HIV AIDS ) , Presence severe malnutrition ( defined child whose growth pattern 3rd percentile , midupperarm circumference &lt; 110mm , weight / height &lt; 70 % accord WHO table , presence bilateral edema lower limb ) Multi monoinfection another Plasmodium specie detect microscopy ; Regular medication may interfere pharmacokinetics antimalarial ; History hypersensitivity contraindication study drug ; A history take antimalarial drug drug antimalarial activity le 7 day . Continuous prophylaxis cotrimoxazole HIV positive child</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>treatment</keyword>
	<keyword>artemisin-based combination</keyword>
	<keyword>child</keyword>
</DOC>